Overview
- The recall, announced on Sept. 10–11, covers two Pantoprazol beta 40 mg magensaftresistente batches: CV250342 (30 tablets) and CV250344 (100 tablets).
- Betapharm says some packs were released without the legally required sign‑off by a qualified person and tests found a deviation in the drug‑release specification for those batches.
- Pharmacies and wholesalers have been instructed to block remaining stock and return affected packs through the supply chain, and apothecaries will be credited for returned items.
- Consumers should have pharmacists check the batch number on their box or blister (look for “Ch.-B.”) and must not stop or change prescriptions without consulting a doctor or pharmacist.
- Authorities including BfArM and the AMK are overseeing the recall, no patient‑level harm has been confirmed, and experts note a release‑deviation alone does not prove reduced efficacy or direct health risk.